Literature DB >> 16055178

Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer.

John K Chan1, Alessandra Magistris, Vera Loizzi, Fritz Lin, Joanne Rutgers, Kathryn Osann, Philip J DiSaia, Michael Samoszuk.   

Abstract

OBJECTIVE: To determine clinical or biological associations between mast cell density, blood clotting, angiogenesis, and survival of patients with advanced ovarian cancer.
METHODS: Tumor tissue sections were assessed for mast cell density by staining for mast cell tryptase, blood clotting by staining of thrombosed blood vessels, and angiogenesis by CD34 expression. Chi-square, Kaplan-Meier, and Cox proportional hazard statistical analyses were used.
RESULTS: 44 women with stage III-IV ovarian cancers had tumor blocks available for immunohistochemical analysis. Higher mean vessel density (MVD) (>11 vessels/400x field) predicted for better survival than lower MVD (< or =11 vessels/400x field) (P = 0.004). Women whose tumors had low levels of peri-tumoral mast cell infiltration had a mean survival of 40.6 months compared to 50.6 months in those whose tumors had high levels (P = 0.47). Tumors with higher MVD and high peri-tumoral mast cell infiltration had a mean survival of 80.3 months compared to 37.8 months in those with low mast cell density or low MVD (P = 0.015). Patients with tumors showing a low degree of blood clotting had a mean survival of 45.5 compared to 45.1 months in those with tumors showing a high degree of blood clotting (P = 0.91). There was no significant association between angiogenesis and mast cell density (P = 0.123). In multivariate analysis, higher MVD remained as a significant prognostic factor for improved survival after adjusting for clotting and mast cell density.
CONCLUSIONS: Our data suggest that peri-tumoral mast cell infiltration in tumors with high MVD predicts for improved survival in women with advanced epithelial ovarian cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16055178     DOI: 10.1016/j.ygyno.2005.05.042

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

Review 1.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

2.  Accumulation of CD1a-positive Langerhans cells and mast cells in actinic cheilitis.

Authors:  Caliandra Pinto Araújo; Clarissa Araújo Silva Gurgel; Eduardo Antônio Gonçalves Ramos; Valéria Souza Freitas; Aryon de Almeida Barbosa; Luciana Maria Pedreira Ramalho; Jean Nunes dos Santos
Journal:  J Mol Histol       Date:  2010-10-02       Impact factor: 2.611

3.  Immune System in Action.

Authors:  Bettzy Stephen; Joud Hajjar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Mast Cell Activation Syndrome in COVID-19 and Female Reproductive Function: Theoretical Background vs. Accumulating Clinical Evidence.

Authors:  Dariusz Szukiewicz; Piotr Wojdasiewicz; Mateusz Watroba; Grzegorz Szewczyk
Journal:  J Immunol Res       Date:  2022-06-22       Impact factor: 4.493

5.  Ovarian cyst fluid of serous ovarian tumors contains large quantities of the brain amino acid N-acetylaspartate.

Authors:  Eva Kolwijck; Ron A Wevers; Udo F Engelke; Jannes Woudenberg; Johan Bulten; Henk J Blom; Leon F A G Massuger
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

6.  Density of mast cells and microvessels in minor salivary gland tumors.

Authors:  Manuela Torres Andion Vidal; Iguaracyra Barreto de Oliveira Araújo; Clarissa Araújo Silva Gurgel; Francisco De Assis Caldas Pereira; Deise Souza Vilas-Bôas; Eduardo Antônio Gonçalves Ramos; Ivan Marcelo Gonçalves Agra; Adna Conceição Barros; Valéria Souza Freitas; Jean Nunes Dos Santos
Journal:  Tumour Biol       Date:  2012-10-20

7.  Significance of neo-angiogenesis and immuno-surveillance cells in squamous cell carcinoma of the tongue.

Authors:  Juma O Alkhabuli
Journal:  Libyan J Med       Date:  2007-03-01       Impact factor: 1.657

Review 8.  Mast Cells: A New Frontier for Cancer Immunotherapy.

Authors:  Jake N Lichterman; Sangeetha M Reddy
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

9.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

10.  Mast cells and angiogenesis in oral malignant and premalignant lesions.

Authors:  E Z Michailidou; A K Markopoulos; D Z Antoniades
Journal:  Open Dent J       Date:  2008-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.